ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Is TRT safe in men who are at high risk for cardiovascular disease?
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 276784" data-attributes="member: 13851"><p>[URL unfurl="true"]https://www.excelmale.com/threads/testosterone-therapy-and-the-risk-of-cardiovascular-disease.30005/[/URL]</p><p></p><p></p><p><strong>4. Conclusion</strong></p><p></p><p><em><em><strong>The therapeutic approach for TT for symptomatic hypogonadism and low testosterone levels associated with aging, obesity, and systemic illness presents challenges. These conditions are intricately linked with CVD outcomes and may confound the relationship between low testosterone and CVD. <u>Although observational studies suggest an association between low testosterone and increased risk of CVD, results from testosterone supplementation are inconsistent</u>. <u>RCTs indicate that short-term TT at standard replacement is not associated with increased CVD risk</u>. <u>Nevertheless, the cardiovascular sub-study of T Trials observed increases in NCP and CAC, signaling the need for further investigation into potential long-term implications of TT</u>.</strong></em></em></p><p><em><em><strong></strong></em></em></p><p><em><em><strong>The TRAVERSE trial, a landmark study unique in its capacity to evaluate CVD events, contributes valuable insights into the short-term safety of TT at lower physiological levels. <u>However, the long-term effects and implications of mid to high physiological testosterone levels are not yet fully understood</u>. <u>The trials’ limitations — achievement of only low-normal testosterone levels, high discontinuation rates, brief follow-up period, and high loss to follow-up rate — suggest that the findings should be interpreted with caution</u>. I<u>t is important to avoid generalizing the safety of TT based on these results alone and to approach the extrapolation of TRAVERSE’s conclusions to higher dosages or longer-term therapy with caution</u>.</strong></em></em></p><p><em><em><strong></strong></em></em></p><p><em><em><strong><u>The decision to initiate TT requires a nuanced approach, which must account for current gaps in evidence regarding CV safety</u>. <u>A personalized assessment and management of CVD risk factors is essential for older men with known CVD</u>. <u>The CV effects of exogenous testosterone, when given to maintain physiological levels, remain to be fully explored</u>. In this regard, an important question remains the identification of male patients with symptomatic hypogonadism who may benefit from TT. This topic continues to be the subject of ongoing debate. <u>Hopefully, future trials will provide clarity on whether TT confers beneficial, neutral, or adverse cardiovascular effects in middle-aged and older men</u>. <u>Until definitive evidence surfaces, clinical practice should exercise caution and prioritize individualized care with informed discussions regarding the potential CV implications of TT</u>.</strong></em></em></p></blockquote><p></p>
[QUOTE="madman, post: 276784, member: 13851"] [URL unfurl="true"]https://www.excelmale.com/threads/testosterone-therapy-and-the-risk-of-cardiovascular-disease.30005/[/URL] [B]4. Conclusion[/B] [I][I][B]The therapeutic approach for TT for symptomatic hypogonadism and low testosterone levels associated with aging, obesity, and systemic illness presents challenges. These conditions are intricately linked with CVD outcomes and may confound the relationship between low testosterone and CVD. [U]Although observational studies suggest an association between low testosterone and increased risk of CVD, results from testosterone supplementation are inconsistent[/U]. [U]RCTs indicate that short-term TT at standard replacement is not associated with increased CVD risk[/U]. [U]Nevertheless, the cardiovascular sub-study of T Trials observed increases in NCP and CAC, signaling the need for further investigation into potential long-term implications of TT[/U]. The TRAVERSE trial, a landmark study unique in its capacity to evaluate CVD events, contributes valuable insights into the short-term safety of TT at lower physiological levels. [U]However, the long-term effects and implications of mid to high physiological testosterone levels are not yet fully understood[/U]. [U]The trials’ limitations — achievement of only low-normal testosterone levels, high discontinuation rates, brief follow-up period, and high loss to follow-up rate — suggest that the findings should be interpreted with caution[/U]. I[U]t is important to avoid generalizing the safety of TT based on these results alone and to approach the extrapolation of TRAVERSE’s conclusions to higher dosages or longer-term therapy with caution[/U]. [U]The decision to initiate TT requires a nuanced approach, which must account for current gaps in evidence regarding CV safety[/U]. [U]A personalized assessment and management of CVD risk factors is essential for older men with known CVD[/U]. [U]The CV effects of exogenous testosterone, when given to maintain physiological levels, remain to be fully explored[/U]. In this regard, an important question remains the identification of male patients with symptomatic hypogonadism who may benefit from TT. This topic continues to be the subject of ongoing debate. [U]Hopefully, future trials will provide clarity on whether TT confers beneficial, neutral, or adverse cardiovascular effects in middle-aged and older men[/U]. [U]Until definitive evidence surfaces, clinical practice should exercise caution and prioritize individualized care with informed discussions regarding the potential CV implications of TT[/U].[/B][/I][/I] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Is TRT safe in men who are at high risk for cardiovascular disease?
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top